Skip to main content
. 2017 Jun 2;8(44):76044–76056. doi: 10.18632/oncotarget.18340

Figure 2. Selective binding of CD133-targeted oncolytic adenoviruses.

Figure 2

(A) Binding specificity of AdML-TYML was analyzed with 293 cells expressing different level of CD133: 293, 293-CD133 (polyclonal mix), isolated clones #9 and #12 (CD133 high expressing clones). The isolated total DNA was analyzed by the E4 qPCR to determine the adenoviral copy number bound to the surface of the cells. The level of CD133 expression was determined by flow-cytometry, and shown below the graph (gray closed curve: unstained, open curve: anti-CD133 Ab) (*P < 0.05). (B) Binding ability of AdML-TYML in human colon cancer cell lines. The flow-cytometry data showing different level of CD133 expression in colon cancer cell lines (LoVo: CD133+, LS174T: CD133-). The results of binding assay were shown as E4 copy number per ng DNA (*P < 0.05). (C) The anti-CD133 antibody significantly inhibited the binding of AdML-TYML to the CD133-positive target cells. (n = 3, *P < 0.05).